• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

慢性肾脏病 5 期且有继发性甲状旁腺功能亢进生化证据的患者是否应使用拟钙剂治疗？欧洲肾脏协会-欧洲透析和移植协会立场声明。

Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement.

机构信息

Renal and Transplantation Department, Guy's and St Thomas' Hospitals, London, UK.

Nephrology Department, Gr. T. Popa University of Medicine and Pharmacy, Iasi, Romania.

出版信息

Nephrol Dial Transplant. 2015 May;30(5):698-700. doi: 10.1093/ndt/gfv050. Epub 2015 Mar 4.

DOI:10.1093/ndt/gfv050
PMID:25928337
Abstract

This paper reflects the position of the CKD-MBD workgroup, an official working group of ERA-EDTA and of the ERBP advisory board, the official guideline-producing body of ERA-EDTA, on the topic of the use of calcimimetics in patients with CKD stage 5D, as based on two recent meta-analysis.

摘要

本文反映了 CKD-MBD 工作组的立场，该工作组是 ERA-EDTA 的一个官方工作组，也是 ERBP 顾问委员会的成员，ERBP 是 ERA-EDTA 的官方指南制定机构，本文基于最近的两项荟萃分析，讨论了在 CKD 5D 期患者中使用钙敏感受体激动剂的问题。

相似文献

1
Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement.慢性肾脏病 5 期且有继发性甲状旁腺功能亢进生化证据的患者是否应使用拟钙剂治疗？欧洲肾脏协会-欧洲透析和移植协会立场声明。
Nephrol Dial Transplant. 2015 May;30(5):698-700. doi: 10.1093/ndt/gfv050. Epub 2015 Mar 4.
2
Integral pharmacological management of bone mineral disorders in chronic kidney disease (part II): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.慢性肾脏病骨矿物质紊乱的综合药物治疗（第二部分）：从磷酸盐失衡的治疗到甲状旁腺激素的控制及心血管钙化进展的预防
Expert Opin Pharmacother. 2016 Jul;17(10):1363-73. doi: 10.1080/14656566.2016.1182985. Epub 2016 May 17.
3
[Calcimimetics, phosphate binders, vitamin D and its analogues for treating secondary hyperparathyroidism in chronic kidney disease: guideline from the Italian Society of Nephrology].[拟钙剂、磷结合剂、维生素D及其类似物治疗慢性肾脏病继发性甲状旁腺功能亢进：意大利肾脏病学会指南]
G Ital Nefrol. 2007 Jan-Feb;24 Suppl 37:S107-24.
4
Optimal TARGETs for cardiovascular safety and benefit in ESRD.终末期肾病心血管安全性和获益的最佳目标
Nephrol Dial Transplant. 2008 Oct;23(10):3370-1; author reply 3371-2. doi: 10.1093/ndt/gfn389. Epub 2008 Jul 22.
5
[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Role of cinacalcet in the treatment of CKD-MBD].[慢性肾脏病-矿物质和骨异常（CKD-MBD）。西那卡塞在CKD-MBD治疗中的作用]
Clin Calcium. 2010 Jul;20(7):1089-95.
6
Management of mineral and bone disorder in chronic kidney disease: quo vadis?慢性肾脏病矿物质和骨异常的管理：何去何从？
Ther Apher Dial. 2009 Oct;13 Suppl 1:S2-6. doi: 10.1111/j.1744-9987.2009.00767.x.
7
[Utilization of alfacalcidol and active vitamin D analogs in chronic kidney disease].[阿法骨化醇及活性维生素D类似物在慢性肾脏病中的应用]
Nephrol Ther. 2018 Jun;14(4):189-200. doi: 10.1016/j.nephro.2017.03.003. Epub 2018 Mar 12.
8
Paricalcitol and cinacalcet have disparate actions on parathyroid oxyphil cell content in patients with chronic kidney disease.帕立骨化醇和西那卡塞对慢性肾脏病患者甲状旁腺嗜酸细胞含量有不同的作用。
Kidney Int. 2017 Nov;92(5):1217-1222. doi: 10.1016/j.kint.2017.05.003. Epub 2017 Jul 24.
9
[Calcimimetic drugs in stage 3-5 chronic kidney disease].[拟钙剂在3-5期慢性肾脏病中的应用]
Pol Merkur Lekarski. 2012 Apr;32(190):260-2.
10
[Basic and clinical aspects of calcimimetics. The clinical effect and usefulness of Cinacalcet as a calcimimetics on three CKD-5D patients undergoing hemodialysis with refractory secondary hyperparathyroidism].拟钙剂的基础与临床研究。西那卡塞作为拟钙剂对3例接受血液透析且伴有难治性继发性甲状旁腺功能亢进的慢性肾脏病5期患者的临床疗效及应用价值
Clin Calcium. 2008 Jan;18(1):81-8.

引用本文的文献

1
Outcome of subtotal parathyroidectomy for surgical treatment of hyperparathyroidism after renal transplantation.肾移植术后甲状旁腺次全切除术治疗甲状旁腺功能亢进症的手术疗效
Braz J Otorhinolaryngol. 2025 Jul;91 Suppl 1(Suppl 1):101623. doi: 10.1016/j.bjorl.2025.101623. Epub 2025 Jun 4.
2
The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism.西那卡塞对重度继发性甲状旁腺功能亢进透析患者矿物质代谢标志物的影响。
J Bras Nefrol. 2019 Jul 18;41(3):336-344. doi: 10.1590/2175-8239-JBN-2018-0219.
3
Effect of extended hours dialysis on markers of chronic kidney disease-mineral and bone disorder in the ACTIVE Dialysis study.
ACTIVE Dialysis 研究中延长透析时间对慢性肾脏病-矿物质和骨异常标志物的影响。
BMC Nephrol. 2019 Jul 12;20(1):258. doi: 10.1186/s12882-019-1438-3.
4
Vitamin D and Calcimimetics in Cardiovascular Disease.维生素 D 与心血管疾病中的钙敏感受体激动剂
Semin Nephrol. 2018 May;38(3):251-266. doi: 10.1016/j.semnephrol.2018.02.005.
5
Calcimimetics versus parathyroidectomy: What is preferable?拟钙剂与甲状旁腺切除术：哪种更可取？
Int Urol Nephrol. 2018 Jul;50(7):1271-1275. doi: 10.1007/s11255-018-1838-5. Epub 2018 Mar 12.
6
Cinacalcet use and the risk of cardiovascular events, fractures and mortality in chronic kidney disease patients with secondary hyperparathyroidism.西那卡塞在慢性肾脏病继发性甲状旁腺功能亢进患者中的应用与心血管事件、骨折和死亡风险的关系。
Sci Rep. 2018 Feb 1;8(1):2103. doi: 10.1038/s41598-018-20552-5.
7
Impact of surgical parathyroidectomy on chronic kidney disease-mineral and bone disorder (CKD-MBD) - A systematic review and meta-analysis.手术甲状旁腺切除术对慢性肾脏病-矿物质和骨异常（CKD-MBD）的影响——一项系统评价和荟萃分析。
PLoS One. 2017 Nov 6;12(11):e0187025. doi: 10.1371/journal.pone.0187025. eCollection 2017.
8
Secondary Hyperparthyroidism: Pathogenesis, Diagnosis, Preventive and Therapeutic Strategies.继发性甲状旁腺功能亢进症：发病机制、诊断、预防和治疗策略。
Rev Endocr Metab Disord. 2017 Mar;18(1):79-95. doi: 10.1007/s11154-017-9421-4.
9
Building on evidence to improve patient care.基于证据改善患者护理。
Pediatr Nephrol. 2017 Dec;32(12):2193-2202. doi: 10.1007/s00467-016-3554-7. Epub 2016 Dec 9.
10
Optimal management of bone mineral disorders in chronic kidney disease and end stage renal disease.慢性肾脏病及终末期肾病中骨矿物质紊乱的优化管理
Curr Opin Nephrol Hypertens. 2016 Mar;25(2):120-6. doi: 10.1097/MNH.0000000000000203.